BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 29980114)

  • 1. Design, synthesis, docking study, α-glucosidase inhibition, and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes.
    Mohammadi-Khanaposhtani M; Rezaei S; Khalifeh R; Imanparast S; Faramarzi MA; Bahadorikhalili S; Safavi M; Bandarian F; Nasli Esfahani E; Mahdavi M; Larijani B
    Bioorg Chem; 2018 Oct; 80():288-295. PubMed ID: 29980114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.
    Asgari MS; Mohammadi-Khanaposhtani M; Kiani M; Ranjbar PR; Zabihi E; Pourbagher R; Rahimi R; Faramarzi MA; Biglar M; Larijani B; Mahdavi M; Hamedifar H; Hajimiri MH
    Bioorg Chem; 2019 Nov; 92():103206. PubMed ID: 31445191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study.
    Saeedi M; Mohammadi-Khanaposhtani M; Pourrabia P; Razzaghi N; Ghadimi R; Imanparast S; Faramarzi MA; Bandarian F; Esfahani EN; Safavi M; Rastegar H; Larijani B; Mahdavi M; Akbarzadeh T
    Bioorg Chem; 2019 Mar; 83():161-169. PubMed ID: 30366316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents.
    Nikookar H; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Ranjbar PR; Mahdavi M; Larijani B
    Bioorg Chem; 2018 Apr; 77():280-286. PubMed ID: 29421703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel pyrazole-phenyl semicarbazone derivatives as potential α-glucosidase inhibitor: Kinetics and molecular dynamics simulation study.
    Azimi F; Ghasemi JB; Azizian H; Najafi M; Faramarzi MA; Saghaei L; Sadeghi-Aliabadi H; Larijani B; Hassanzadeh F; Mahdavi M
    Int J Biol Macromol; 2021 Jan; 166():1082-1095. PubMed ID: 33157144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel pyridazine N-aryl acetamides: In-vitro evaluation of α-glucosidase inhibition, docking, and kinetic studies.
    Moghimi S; Toolabi M; Salarinejad S; Firoozpour L; Sadat Ebrahimi SE; Safari F; Mojtabavi S; Faramarzi MA; Foroumadi A
    Bioorg Chem; 2020 Sep; 102():104071. PubMed ID: 32688112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
    Riaz S; Khan IU; Bajda M; Ashraf M; Qurat-Ul-Ain ; Shaukat A; Rehman TU; Mutahir S; Hussain S; Mustafa G; Yar M
    Bioorg Chem; 2015 Dec; 63():64-71. PubMed ID: 26451651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, molecular modelling, ADME prediction and anti-hyperglycemic evaluation of new pyrazole-triazolopyrimidine hybrids as potent α-glucosidase inhibitors.
    Pogaku V; Gangarapu K; Basavoju S; Tatapudi KK; Katragadda SB
    Bioorg Chem; 2019 Dec; 93():103307. PubMed ID: 31585262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, in vitro evaluation, and molecular docking studies of novel hydrazineylideneindolinone linked to phenoxymethyl-1,2,3-triazole derivatives as potential α-glucosidase inhibitors.
    Shareghi-Boroujeni D; Iraji A; Mojtabavi S; Faramarzi MA; Akbarzadeh T; Saeedi M
    Bioorg Chem; 2021 Jun; 111():104869. PubMed ID: 33839583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potential α-glucosidase inhibitors.
    Wang G; Peng Z; Wang J; Li X; Li J
    Eur J Med Chem; 2017 Jan; 125():423-429. PubMed ID: 27689725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel xanthone-triazole derivatives as potential antidiabetic agents: α-Glucosidase inhibition and glucose uptake promotion.
    Ye GJ; Lan T; Huang ZX; Cheng XN; Cai CY; Ding SM; Xie ML; Wang B
    Eur J Med Chem; 2019 Sep; 177():362-373. PubMed ID: 31158750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new entry into the portfolio of α-glucosidase inhibitors as potent therapeutics for type 2 diabetes: Design, bioevaluation and one-pot multi-component synthesis of diamine-bridged coumarinyl oxadiazole conjugates.
    Kazmi M; Zaib S; Ibrar A; Amjad ST; Shafique Z; Mehsud S; Saeed A; Iqbal J; Khan I
    Bioorg Chem; 2018 Apr; 77():190-202. PubMed ID: 29421697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tetrahydrobenzo[b]thiophen-2-yl)urea derivatives as novel α-glucosidase inhibitors: Synthesis, kinetics study, molecular docking, and in vivo anti-hyperglycemic evaluation.
    Xie HX; Zhang J; Li Y; Zhang JH; Liu SK; Zhang J; Zheng H; Hao GZ; Zhu KK; Jiang CS
    Bioorg Chem; 2021 Oct; 115():105236. PubMed ID: 34411978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New 6-amino-pyrido[2,3-d]pyrimidine-2,4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, α-glucosidase inhibition, molecular modeling and kinetic study.
    Adib M; Peytam F; Rahmanian-Jazi M; Mahernia S; Bijanzadeh HR; Jahani M; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Mahdavi M; Larijani B
    Eur J Med Chem; 2018 Jul; 155():353-363. PubMed ID: 29902721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Coumarin Containing Dithiocarbamate Derivatives as Potent α-Glucosidase Inhibitors for Management of Type 2 Diabetes.
    Mollazadeh M; Mohammadi-Khanaposhtani M; Valizadeh Y; Zonouzi A; Faramarzi MA; Kiani M; Biglar M; Larijani B; Hamedifar H; Mahdavi M; Hajimiri MH
    Med Chem; 2021; 17(3):264-272. PubMed ID: 32851964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation and molecular docking study of N-arylbenzo[d]oxazol-2-amines as potential α-glucosidase inhibitors.
    Wang G; Peng Z; Wang J; Li J; Li X
    Bioorg Med Chem; 2016 Nov; 24(21):5374-5379. PubMed ID: 27614916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Dual Inhibitory Activity of Novel Anthranilic Acid Derivatives towards α-Glucosidase and Glycogen Phosphorylase Antidiabetic Targets: Design, In Vitro Enzyme Assay, and Docking Studies.
    Ihmaid S
    Molecules; 2018 May; 23(6):. PubMed ID: 29844263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrano[3,2-c]quinoline Derivatives as New Class of α-glucosidase Inhibitors to Treat Type 2 Diabetes: Synthesis, in vitro Biological Evaluation and Kinetic Study.
    Heydari Z; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Mahdavi M; Ranjbar PR; Larijani B
    Med Chem; 2019; 15(1):8-16. PubMed ID: 29807519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, in vitro evaluation and molecular docking studies of novel coumarin-isatin derivatives as α-glucosidase inhibitors.
    Wang G; Wang J; He D; Li X; Li J; Peng Z
    Chem Biol Drug Des; 2017 Mar; 89(3):456-463. PubMed ID: 27616456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and studies of thiazolidinedione-isatin hybrids as α-glucosidase inhibitors for management of diabetes.
    Kaur R; Kumar R; Dogra N; Kumar A; Yadav AK; Kumar M
    Future Med Chem; 2021 Mar; 13(5):457-485. PubMed ID: 33506699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.